Sanofi Stock News

Shares of Adagene Inc. jumped 11.2% in premarket trading on Wednesday after it announced a licensing and commercialization deal with Sanofi that is worth up to $2.5 billion. U.S.-listed shares of Sanofi were down 1.5%. Adagene will develop masked versions of up to four of Sanofi''s antibodies in development. Per the terms of the deal, Sanofi will pay Adadene $17.5 million now; however, the milestone payments are worth up to $2.5 billion, and the company is eligible for royalties based on sales of the therapies if they are commercialized. Adagene''s stock has tumbled 77.6% over the past year, while the S&P 500 is up 10.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endometrial Cancer Karyopharm Therapeutics, Inc. (NASDAQ: KPTI ) said following discussions with the U.S. Food and Drug Administration regarding its previously planned supplemental new drug Application for selinexor in advanced or recurrent endometrial cancer , the regulator conveyed that topline results from the Phase 3 SIENDO study are unlikely to support approval. The regulator said further exploration of patients with advanced or recurrent endometrial cancer with p53 wild-type is warranted. Taking into account, the FDA''s feedback, the company intends to initiate a new study of selinexor in patients with p53 wild-type endometrial cancer and believes top-line data will be available in the first half of 2024. The stock was slumping 26.95% to $7.59 in premarket trading. Finch Pauses Phase 3 Study Of Microbiome Therapeutic CP101 Following FDA''s Clinical Hold Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) announced that it has paused enrollment in PRISM4 Phase 3 clinical trial of CP101 in recurrent C. difficile infection following the receipt of a clinical hold letter from FDA on Feb. 24, requesting additional information about Finch''s SARS-CoV-2 donor screening protocols.

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in people with pyruvate kinase deficiency. Hemolysis refers to the destruction of red blood cells. Pyrukynd is a "new molecular entity," a term that refers to a drug containing an active moiety that hasn''t been previously approved by the FDA. NME approval, therefore, is considered a measure of innovation in drug research. Another NME that passed the FDA hurdle was Sanofi''s (NASDAQ: SNY ) Enjaymo for the treatment of hemolysis in adults with cold agglutinin disease. Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), as expected, received a complete response letter for its new drug application for bardoxolone methyl as a treatment option for Alport syndrome. An Adcom that met in early December voted against recommending approval of the drug.

The ADRs of Adagene (ADAG) have climbed ~17% in the pre-market Tuesday after the China-based clinical-stage biopharmaceutical company announced a partnership with Frech pharma giant…

Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates - Total potential transaction value… | March 2, 2022

- Total potential transaction value of $2.5 billion plus royalties -

GlaxoSmithKline PLC found using ticker (GSK) have now 2 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 51.5 and 45.64 with a mean TP of 48.57. With the stocks previous close at 41.86 this now indicates there is a potential upside of 16.0%. The 50 day MA is 44.16 and the 200 day MA is 41.31. The company has a market capitalisation of $105,612m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets=GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $122,541m based on the market concensus. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.

Shares of Adagene Inc. ADAG, +1.10% jumped 11.2% in premarket trading on Wednesday after it announced a licensing and commercialization deal with Sanofi SNY, -2.65% that is worth up to $2.5 billion. U

Image sourced from Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. DarioHealth Corp. (NASDAQ: DRIO ) announced that it has entered into a strategic agreement with Sanofi U.S., an innovative global healthcare company. The multi-year, $30 million-dollar agreement, which is subject to certain contingencies, will help accelerate commercial adoption of Dario''s full suite of digital therapeutics and drive the expansion of digital health solutions on the Dario platform. Dario and Sanofi will collaborate on promoting the Dario multi-condition digital therapeutics solution, significantly increasing Dario''s sales reach in the health plan market and selectively in the employer channel. In addition, the agreement calls for Dario and Sanofi to develop new … Full story available on Benzinga.com

DarioHealth (DRIO) signed a $30M strategic agreement with Sanofi U.S

LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO ), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company''s Board of Directors, effective immediately. Ms. Hyland has also been appointed to serve on the Audit and Risk Committee of the Board. Ms. Hyland joins Mereo''s Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space. "We are very excited to welcome someone with Anne''s level of operational and board experience to our Board," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "Anne is a proven industry leader whose strong finance and business experience in the biopharmaceutical industry will be invaluable as Mereo continues to build and execute on our mission of developing and delivering groundbreaking therapeutics for oncology and rare disease patients." Ms.

PARIS, France: A spokesperson for Sanofi announced positive results from late-stage clinical trials of a new vaccine it developed with GSK, named Vidprevtyn. The results were posted in company news releases, and the manufacturers said full results will be published this year. The two European drug makers plan to seek authorization for use of the vaccine in the U.S. and Europe. Vidprevtyn is a prote

Wide-Moat Stocks On Sale - The March 2022 Heat Map

A protein-based vaccine that GlaxoSmithKline and Sanofi hope to get approved has several advantages over mRNA-based vaccines made by companies like Moderna and Pfizer.

Watch Video European drugmakers Sanofi and Glaxosmithkline (GSK) released data showing their COVID vaccine is 100% effective at keeping patients out of the hospital. It has not been independently scientifically reviewed. Drugmakers Sanofi and GlaxoSmithKline have asked the Food and Drug Administration for emergency use authorization of their vaccine. "We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period," Roger Connor, president of GSK, said in a statement. Sanofi''s and GSK''s vaccine is based on a more conventional protein-based vaccine technology. It''s a recombinant protein vaccine, which means it recombines different segments of DNA. This uses DNA from the SARS-COV-2 spike protein, which COVID needs to enter and infect healthy cells. The combined DNA helps fire up your immune response. This is different from Pfizer and Moderna''s mRNA, or messenger RNA, technology. That vaccine uses a genetic code to teach the body''s cells how to make proteins that trigger immune responses.